Performance and hormones moved differently
Sixteen men were assigned to sprint training or a control group. After six weeks, the training group improved peak and mean cycling power while its exercise-associated GH response became smaller. Resting GH did not change. The experiment involved training, not sermorelin or another peptide treatment. [1]
The result is useful because it places a functional measure beside a hormone measure instead of assuming one represents the other. A favorable adaptation can have a more complicated physiological signature than a single upward arrow on a laboratory chart.
A hormone peak is not a training score
Our interpretation is that ranking exercise programs by the size of an acute GH response would have misrepresented this study’s performance result. The measured hormone response and the desired activity outcome were not interchangeable indicators. That is a concrete reason to keep outcome selection tied to the question being asked.
For someone interested in a peptide because of gym performance, a change in a hormone is not enough. Ask whether the evidence measured the relevant performance task and compared it with a credible alternative. A body-composition measurement or subjective recovery report answers a different question from power or strength.
Do not infer that less GH caused the improvement
The experiment does not establish that reducing GH is a strategy for improving performance. Both observations occurred after training, but that does not prove the smaller hormonal response caused the better output. Replacing one simplistic story with its opposite would repeat the same reasoning error.
The appropriate conclusion is narrower: in this protocol, the outcomes did not support using the acute hormone response as a simple proxy for training success. Our older-adult training study examines a related measurement question in a different population and over a longer period.
Define the performance claim before judging it
A claim about recovery should specify whether it means less soreness, readiness for another session, sustained training capacity or improvement on a test. These are not the same endpoint. Once the claim is explicit, readers can ask whether the cited research actually measured it.
Our GH-plus-training trial guide asks whether adding a hormone improved strength beyond training. Neither paper supplies a sermorelin efficacy estimate, but both help identify the evidence a performance claim needs. For a personal decision, prioritize the activity you want to improve and the clinician’s evaluation of that goal rather than treating an acute hormone peak as the final outcome.
Performance testing also needs consistency: comparing unlike tasks or different conditions can create a misleading personal before-and-after story. A meaningful goal should be measured in a way that reflects the activity, rather than inferred from whichever laboratory number changed most.